Tradestie Institutional Equity Comparison Engine

PVLA vs SYRE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SYRE Overall Edge

SYRE Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Spyre Therapeutics, Inc. Common Stock (SYRE) driven by superior Growth & Margin, Momentum & Technical while PVLA counters with relative strength in Options & Structure. Fundamentally, PVLA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus SYRE at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, PVLA sits in CONSOLIDATION (2nd %ile IV; Dealer Gamma Walls on Pro) against SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
PVLA N/M vs SYRE N/M Fwd P/E
Growth & Margin Winner SYRE
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner SYRE
1Y +80.2% vs +341.7% ยท 52W Pos 68% vs 88%
Options & Structure Winner PVLA
CONSOLIDATION (2nd %ile IV) vs UNCLASSIFIED (10th %ile IV)
PVLA NASDAQ
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap $2.2B
1M Return +20.56%
1Y Return +80.16%
Forward P/E N/M
Unified AI Score
48.2 / 100 HOLD
Tech 35.0 Fund 53.0 Flow 67.0 Mom 60.0
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
1M Return +25.11%
1Y Return +341.74%
Forward P/E N/M
Unified AI Score
36.1 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: PVLA +80.16% SYRE +341.74% Spread: +261.58 pp (SYRE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
PVLA TTM Op. Margin: 0.0% SYRE TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PVLA vs SYRE. Trailing 12-month operating profitability (PVLA 0.0% vs SYRE 0.0%) and valuation multiples (PVLA N/M vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: PVLA (1) vs SYRE (4)
Institutional Metric PVLA SYRE Criterion Row Winner
Market Capitalization Scale $2.2B $9.8B Larger Scale SYRE
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -63.4% -35.0% Higher ROE SYRE
52-Week Range Position Momentum 68% ($72โ€“$180) 88% ($22โ€“$111) Stronger Trend SYRE
Beta / 30D Volatility Risk Regime 1.66ฮฒ ยท 75% Vol 1.75ฮฒ ยท 59% Vol Lower Realized Risk SYRE
Unified Institutional Score Composite Signal 48.2 / 100 (HOLD) 36.1 / 100 (SELL) Higher Composite PVLA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full PVLA vs SYRE Buy Guide
PVLA CONSOLIDATION
70d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 2nd %ile
IV Regime Compressed (<25th %ile)
Live PVLA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SYRE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live SYRE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither PVLA nor SYRE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.